Trial Profile
A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Larazotide (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors 9 Meters Biopharma [CEASED]; Alba Therapeutics
- 12 Dec 2014 New trial record